Conjunctival Concentrations of a New Ophthalmic Solution Formulation of Moxifloxacin 0.5% in Cataract Surgery Patients

被引:3
作者
Lindstrom, Richard [2 ]
Lane, Stephen [3 ]
Cottingham, Andrew [4 ]
Smith, Stephen [5 ]
Sall, Kenneth [6 ]
Silverstein, Steven [7 ]
Shettle, Lee [8 ]
Walters, Thomas [9 ]
Faulkner, Robert [1 ]
Cockrum, Paul [1 ]
Teuscher, Nathan [1 ]
机构
[1] Alcon Res Ltd, Ft Worth, TX 76134 USA
[2] Minnesota Eye Consultants, Minneapolis, MN USA
[3] Associated Eye Care, Stillwater, MN USA
[4] Texas Quest Med Res, San Antonio, TX USA
[5] Eye Associates Ft Myers, Ft Myers, FL USA
[6] Sall Eye Res Med Ctr, Artesia, CA USA
[7] Silverstein Eye Ctr, Kansas City, MO USA
[8] Shettle Eye Ctr, Largo, FL USA
[9] Texan Eye, Austin, TX USA
关键词
BACTERIAL CONJUNCTIVITIS; TISSUE;
D O I
10.1089/jop.2010.0089
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To compare the conjunctival concentrations of moxifloxacin after instillation of a single drop of moxifloxacin ophthalmic solution, 0.5% (Moxi) or a new 0.5% ophthalmic solution formulation (MAF) containing a retention-enhancing agent in patients undergoing cataract surgery. Methods: This was a randomized, double-masked, parallel-group study. One hundred thirty patients scheduled for routine phacoemulsification and intraocular lens implantation were randomized to both treatment and post-dose sample collection time points. A single topical drop of Moxi or MAF was instilled in the study eye. At the designated time (0.25, 0.5, 1, 3, or 5 h post-dose), 2 conjunctival biopsy samples were obtained (N - 11-13 per treatment condition). Concentrations of moxifloxacin were determined using a validated ultra-performance liquid chromatography method. Moxifloxacin exposure [maximum mean moxifloxacin concentrations (C-max) and area under the concentration-time curve (AUC)] was estimated from the observed concentration-time data. Results: The conjunctival moxifloxacin C-max, 43.8 mu g/g, for MAF was achieved at 0.25 h. This was 1.8-fold higher than the Cmax for Moxi (24.1 mu g/g), which was reached at 0.5 h post-dose. MAF AUC(0-3) was significantly greater than the AUC(0-3) of Moxi [50.5 (mu g.h)/g vs. 27.1 (mu g.h)/g; P < 0.05]. The conjunctival moxifloxacin C-max for MAF was 337-to 730-fold greater than the reported minimum inhibitory concentration (MIC90) values for Staphylococcus aureus, Streptococcus pneumoniae, and Haemophilus influenzae. The Cmax:MIC90 ratios for Moxi ranged from 185 to 402. Conjunctival AUC(0-24):MIC90 ratios ranged from 777 to 1,683 for MAF and from 625 to 1,355 for Moxi. Conclusions: The new MAF ophthalmic formulation of moxifloxacin provided higher peak levels of moxifloxacin in the conjunctiva tissue, and larger total tissue exposure than the current, commercially available formulation. The superior penetration of MAF observed in this study could translate into greater eradication of bacteria.
引用
收藏
页码:591 / 595
页数:5
相关论文
共 10 条
[1]   A Comparison of Fluoroquinolone Penetration into Human Conjunctival Tissue [J].
Aihara, Makoto ;
Miyanaga, Masaru ;
Minami, Keiichiro ;
Miyata, Kazunori ;
Eguchi, Shuichiro ;
Shiroma, Hiroki ;
Sawaguchi, Shoichi .
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2008, 24 (06) :587-591
[2]   Ophthalmic infections and their anti-infective challenges [J].
Alfonso, E ;
Crider, J .
SURVEY OF OPHTHALMOLOGY, 2005, 50 :S1-S6
[3]   TESTING FOR THE EQUALITY OF AREA UNDER THE CURVES WHEN USING DESTRUCTIVE MEASUREMENT TECHNIQUES [J].
BAILER, AJ .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1988, 16 (03) :303-309
[4]   Update on bacterial conjunctivitis in south Florida [J].
Cavuoto, Kara ;
Zutshi, Deepti ;
Karp, Carol L. ;
Miller, Darlene ;
Feuer, William .
OPHTHALMOLOGY, 2008, 115 (01) :51-56
[5]  
Mah Francis S, 2004, Curr Opin Ophthalmol, V15, P316, DOI 10.1097/00055735-200408000-00007
[6]   Comparison of azithromycin and moxifloxacin against bacterial isolates causing conjunctivitis [J].
Ohnsman, Christina ;
Ritterband, David ;
O'Brien, Terrence ;
Girgis, Dalia ;
Kabat, Al .
CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (09) :2241-2249
[7]   Antibiotics versus placebo for acute bacterial conjunctivitis [J].
Sheikh, A. ;
Hurwitz, B. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2006, (02)
[8]  
STROMAN DW, 2006, HUMAN OCULAR CONCENT
[9]   Evaluation of moxifloxacin, ciprofloxacin, gatifloxacin, ofloxacin, and levofloxacin concentrations in human conjunctival tissue [J].
Wagner, RS ;
Abelson, MB ;
Shapiro, A ;
Torkildsen, G .
ARCHIVES OF OPHTHALMOLOGY, 2005, 123 (09) :1282-1283
[10]   Clinical implications of pharmacokinetics and pharmacodynamics of fluoroquinolones [J].
Wispelwey, B .
CLINICAL INFECTIOUS DISEASES, 2005, 41 :S127-S135